Phase III ELIPSE HoFH trial results of REGN 1500 met primary endpoint in homozygous familial hypercholesterolemia.- Regeneron Pharma
Regeneron Pharmaceuticals announced that detailed Phase III ELIPSE HoFH trial results of REGN 1500 (evinacumab) in patients with homozygous familial hypercholesterolemia (HoFH). The data showed the trial met… read more.